TXG Stock Chart & Stats
$335.54
$0.00(0.00%)
At close: 4:00 PM EDT
$335.54
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$214.00 - $812.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$108.86B
Enterprise Value$2.27K
Total Cash (Recent Filing)$539.85M
Total Debt (Recent Filing)$81.39M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Aug 06, 2026EPS Estimate
-4.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding116,877,320
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)2.56
Price to Sales (P/S)3.17
P/FCF Ratio15.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$697.90Price Target Upside107.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)-14.01
Revenue Forecast (FY)$10.67B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables GrowthSustained double-digit consumables growth, particularly a 31% uplift in spatial consumables, indicates a durable recurring revenue stream. Consumables drive repeat purchases per installed instrument, supporting predictable revenue and margin leverage over the next several quarters as adoption expands.
Resilient Balance Sheet & CashLow leverage and a substantial equity cushion reduce financing risk and provide runway for R&D, inventory build, and instrument ramp. A stronger cash position supports strategic investments, commercialization of Atara, and weathering near-term revenue variability without pressing liquidity constraints.
Product Leadership & Platform Expansion (Atara)Atara represents a structural product upgrade with an upgradable roadmap and high throughput per instrument, potentially expanding TAM and future consumables per user. Early preorder interest and planned feature roadmap (automation, multiomics, cloud) bolster long-term platform stickiness and translational adoption.
Bears Say
Revenue Decline & Ongoing LossesA large trailing revenue contraction and continued operating losses limit the company's ability to leverage fixed costs and translate gross-margin strength into net profitability. Sustained top-line weakness can impede reinvestment, slow R&D commercialization, and delay durable earnings recovery.
Constrained Atara Production CapacityA limited early production run delays Atara's contribution to instrument and consumables revenue. This constrains near-term scaling of a flagship product that underpins future consumables pull-through, making meaningful revenue and adoption tailwinds dependent on successful, timely manufacturing ramp.
Margin & Mix Risk; Platform CannibalizationLower-margin instrument sales and possible migration from legacy spatial platforms can compress overall gross margins and reduce per-instrument consumables demand. Combined with input-cost pressures, these structural mix shifts could temper margin sustainability even as consumables volumes rise.
10x Genomics News
TXG FAQ
What was 10x Genomics Inc’s price range in the past 12 months?
10x Genomics Inc lowest stock price was $214.00 and its highest was $812.00 in the past 12 months.
What is 10x Genomics Inc’s market cap?
10x Genomics Inc’s market cap is $108.86B.
When is 10x Genomics Inc’s upcoming earnings report date?
10x Genomics Inc’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were 10x Genomics Inc’s earnings last quarter?
10x Genomics Inc released its earnings results on May 07, 2026. The company reported -$1.735 earnings per share for the quarter, beating the consensus estimate of -$4.771 by $3.036.
Is 10x Genomics Inc overvalued?
According to Wall Street analysts 10x Genomics Inc’s price is currently Undervalued.
Does 10x Genomics Inc pay dividends?
10x Genomics Inc does not currently pay dividends.
What is 10x Genomics Inc’s EPS estimate?
10x Genomics Inc’s EPS estimate is -4.22.
How many shares outstanding does 10x Genomics Inc have?
10x Genomics Inc has 116,877,320 shares outstanding.
What happened to 10x Genomics Inc’s price movement after its last earnings report?
10x Genomics Inc reported an EPS of -$1.735 in its last earnings report, beating expectations of -$4.771. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of 10x Genomics Inc?
Currently, no hedge funds are holding shares in MX:TXG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
10x Genomics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$697.90 (107.99% Upside)
$697.90 (107.99% Upside)
Blogger Sentiment
Neutral
MX:TXG Sentiment 60%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
236.99%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
12.44%
Trailing 12-Months
Company Description
10x Genomics Inc
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
TXG Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized a major product milestone (Atara) with strong consumables momentum, margin improvement, expense discipline, and a strengthened cash position, balanced against notable near-term headwinds in instrument revenue, limited initial Atara production capacity, and modest full-year growth guidance. Management framed the instrument declines as temporary and incorporated anticipated customer timing shifts into guidance, while positioning Atara and existing platforms to drive longer-term TAM expansion, AI-driven demand, and translational adoption.View all MX:TXG earnings summariesTXG Revenue Breakdown
60.32% Americas
22.99% EMEA
8.45% Asia-Pacific excluding China
8.24% China
TXG Stock 12 Month Forecast
Average Price Target
$697.90
▲(107.99% Upside)